590 related articles for article (PubMed ID: 31249451)
1. Plasma Nogo-A and placental growth factor levels are associated with portal hypertension in patients with liver cirrhosis.
Gelman S; Salteniene V; Pranculis A; Skieceviciene J; Zykus R; Petrauskas D; Kupcinskas L; Canbay A; Link A; Kupcinskas J
World J Gastroenterol; 2019 Jun; 25(23):2935-2946. PubMed ID: 31249451
[TBL] [Abstract][Full Text] [Related]
2. Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver disease.
Simbrunner B; Stadlmann A; Schwabl P; Paternostro R; Bauer DJM; Bucsics T; Scheiner B; Lampichler K; Wöran K; Beer A; Eigenbauer E; Pinter M; Stättermayer AF; Marculescu R; Szekeres T; Trauner M; Mandorfer M; Reiberger T
Dig Liver Dis; 2021 Mar; 53(3):345-352. PubMed ID: 33032973
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of portal hypertension by real-time shear wave elastography in cirrhotic patients.
Kim TY; Jeong WK; Sohn JH; Kim J; Kim MY; Kim Y
Liver Int; 2015 Nov; 35(11):2416-24. PubMed ID: 25875718
[TBL] [Abstract][Full Text] [Related]
4. Osteopontin: A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis.
Bruha R; Jachymova M; Petrtyl J; Dvorak K; Lenicek M; Urbanek P; Svestka T; Vitek L
World J Gastroenterol; 2016 Mar; 22(12):3441-50. PubMed ID: 27022226
[TBL] [Abstract][Full Text] [Related]
5. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis.
Ferlitsch M; Reiberger T; Hoke M; Salzl P; Schwengerer B; Ulbrich G; Payer BA; Trauner M; Peck-Radosavljevic M; Ferlitsch A
Hepatology; 2012 Oct; 56(4):1439-47. PubMed ID: 22532296
[TBL] [Abstract][Full Text] [Related]
6. The usefulness of non-invasive liver stiffness measurements in predicting clinically significant portal hypertension in cirrhotic patients: Korean data.
Hong WK; Kim MY; Baik SK; Shin SY; Kim JM; Kang YS; Lim YL; Kim YJ; Cho YZ; Hwang HW; Lee JH; Chae MH; Kim HA; Kang HW; Kwon SO
Clin Mol Hepatol; 2013 Dec; 19(4):370-5. PubMed ID: 24459641
[TBL] [Abstract][Full Text] [Related]
7. Endogenous motion of liver correlates to the severity of portal hypertension.
Gelman S; Sakalauskas A; Zykus R; Pranculis A; Jurkonis R; Kuliavienė I; Lukoševičius A; Kupčinskas L; Kupčinskas J
World J Gastroenterol; 2020 Oct; 26(38):5836-5848. PubMed ID: 33132638
[TBL] [Abstract][Full Text] [Related]
8. Non-invasive aspartate aminotransferase to platelet ratio index correlates well with invasive hepatic venous pressure gradient in cirrhosis.
Kirnake V; Arora A; Sharma P; Goyal M; Chawlani R; Toshniwal J; Kumar A
Indian J Gastroenterol; 2018 Jul; 37(4):335-341. PubMed ID: 30178093
[TBL] [Abstract][Full Text] [Related]
9. Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient.
Jachs M; Hartl L; Simbrunner B; Semmler G; Balcar L; Hofer BS; Schwarz M; Bauer D; Stättermayer AF; Pinter M; Trauner M; Reiberger T; Mandorfer M
J Hepatol; 2024 May; 80(5):744-752. PubMed ID: 38218352
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.
Lens S; Baiges A; Alvarado-Tapias E; LLop E; Martinez J; Fortea JI; Ibáñez-Samaniego L; Mariño Z; Rodríguez-Tajes S; Gallego A; Bañares R; Puente Á; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; García-Pagán JC; Forns X
J Hepatol; 2020 Dec; 73(6):1415-1424. PubMed ID: 32535060
[TBL] [Abstract][Full Text] [Related]
11. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis.
Lens S; Alvarado-Tapias E; Mariño Z; Londoño MC; LLop E; Martinez J; Fortea JI; Ibañez L; Ariza X; Baiges A; Gallego A; Bañares R; Puente A; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; Forns X; García-Pagán JC
Gastroenterology; 2017 Nov; 153(5):1273-1283.e1. PubMed ID: 28734831
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease.
Pons M; Augustin S; Scheiner B; Guillaume M; Rosselli M; Rodrigues SG; Stefanescu H; Ma MM; Mandorfer M; Mergeay-Fabre M; Procopet B; Schwabl P; Ferlitsch A; Semmler G; Berzigotti A; Tsochatzis E; Bureau C; Reiberger T; Bosch J; Abraldes JG; Genescà J
Am J Gastroenterol; 2021 Apr; 116(4):723-732. PubMed ID: 33982942
[TBL] [Abstract][Full Text] [Related]
13. Correlation of transient elastography with hepatic venous pressure gradient in patients with cirrhotic portal hypertension: A study of 326 patients from India.
Kumar A; Khan NM; Anikhindi SA; Sharma P; Bansal N; Singla V; Arora A
World J Gastroenterol; 2017 Jan; 23(4):687-696. PubMed ID: 28216976
[TBL] [Abstract][Full Text] [Related]
14. Liver and spleen transient elastography predicts portal hypertension in patients with chronic liver disease: a prospective cohort study.
Zykus R; Jonaitis L; Petrenkienė V; Pranculis A; Kupčinskas L
BMC Gastroenterol; 2015 Dec; 15():183. PubMed ID: 26702818
[TBL] [Abstract][Full Text] [Related]
15. von Willebrand factor as a biomarker of clinically significant portal hypertension and severe portal hypertension: a systematic review and meta-analysis.
Zou Z; Yan X; Li C; Li X; Ma X; Zhang C; Ju S; Tian J; Qi X
BMJ Open; 2019 Aug; 9(8):e025656. PubMed ID: 31473610
[TBL] [Abstract][Full Text] [Related]
16. The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test.
Hametner S; Ferlitsch A; Ferlitsch M; Etschmaier A; Schöfl R; Ziachehabi A; Maieron A
PLoS One; 2016; 11(2):e0149230. PubMed ID: 26895398
[TBL] [Abstract][Full Text] [Related]
17. Clinical Evaluation and Prognosis.
Hernández-Gea V; Berzigotti A
Dig Dis; 2015; 33(4):515-23. PubMed ID: 26159268
[TBL] [Abstract][Full Text] [Related]
18. Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors.
Llop E; Berzigotti A; Reig M; Erice E; Reverter E; Seijo S; Abraldes JG; Bruix J; Bosch J; García-Pagan JC
J Hepatol; 2012 Jan; 56(1):103-8. PubMed ID: 21827733
[TBL] [Abstract][Full Text] [Related]
19. Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis.
Lisotti A; Azzaroli F; Buonfiglioli F; Montagnani M; Cecinato P; Turco L; Calvanese C; Simoni P; Guardigli M; Arena R; Cucchetti A; Colecchia A; Festi D; Golfieri R; Mazzella G
Hepatology; 2014 Feb; 59(2):643-50. PubMed ID: 24038116
[TBL] [Abstract][Full Text] [Related]
20. Novel serum biomarker of Golgi protein 73 for the diagnosis of clinically significant portal hypertension in patients with compensated cirrhosis.
Liu S; Ma J; Chen P; Liu S; Guo Y; Tan M; Guo X; Feng Y; Wang Q; Li W; Yang C; Gao B; Hua Y; Liu N; Song H; He R; Wang R; Gao Q; Liu C; Qi X
J Med Virol; 2024 Jan; 96(1):e29380. PubMed ID: 38235849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
